Skip to main content
Jason Luke, MD, Oncology, Pittsburgh, PA, UPMC Presbyterian Shadyside

JasonLukeMDFACP

Oncology • Pittsburgh, PA

Melanoma

Associate Director for Clinical Research and Associate Professor of Medicine, UPMC Hillman Cancer Center and University of Pittsburgh

Join to view full profile

Dr. Luke is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Luke's full profile

Already have an account?

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
  • Boston University Medical Center
    Boston University Medical CenterResidency, Internal Medicine, 2006 - 2009
  • Chicago Medical School at Rosalind Franklin University of Medicine and Science
    Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2006
  • University of Iowa
    University of IowaB.S., Microbiology, With Honors, 1998 - 2002

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2019 - 2024
  • IL State Medical License
    IL State Medical License 2014 - 2020
  • MA State Medical License
    MA State Medical License 2008 - 2016
  • NY State Medical License
    NY State Medical License 2009 - 2012
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Denise and Michael Kellen-Melanoma Research Alliance Young Investigator 2014
  • Merit Award American Society of Clinical Oncology (ASCO), 2011
  • Young Investigator Award Conquer Cancer Foundation of ASCO, 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • T Cell–Inflamed Versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection  
    Jason J. Luke, Randy F. Sweis, Clinical Cancer Research
  • ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid t...  
    Luke JJ, LoRusso P, Shapiro GI, Krivoshik A, Schuster R, Yamazaki T, Arai Y, Fakhoury A, Dmuchowski C, Infante JR, Cancer Chemother Pharmacol., 1/25/2016
  • New Drugs and Treatment Approaches for Advanced Melanoma: Now that we have effective drugs, how should we combine them?  
    Luke JJ, Hodi FS, Ott PA, Skin Cancer Foundation Journal, 1/1/2014
  • Join now to see all

Abstracts/Posters

  • "Molecularly targeted strategies for advanced ocular melanoma"
    Jason J. Luke, MD, CURE OM Scientific Meeting, Orlando, FL, 1/1/2014
  • "Key Issues in the Clinical Development of Immunotherapy Combinations"
    Jason J. Luke, MD, Combination Cancer Immunotherapy Conference, The 9th Annual Immunotherapies and Vaccine Summit, Boston, MA, 1/1/2014
  • "Uveal melanoma: unique biology and treatment opportunities"
    Jason J. Luke, MD, Beijing international Melanoma Congress, Beijing, People's Republic of China, 1/1/2014
  • Join now to see all

Lectures

  • A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresec... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Phase 1, open-label, adaptive biomarker trial that informs the evolution of combination immuno-oncology (IO) therapies (ADVISE), a precision IO approach to personalize... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Join now to see all

Other

Press Mentions

  • Adding New Vaccine Type to Leading Immunotherapy Dramatically Reduced Melanoma Recurrence
    Adding New Vaccine Type to Leading Immunotherapy Dramatically Reduced Melanoma RecurrenceApril 16th, 2023
  • Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor
    Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical AdvisorOctober 18th, 2022
  • Adjuvant Nivolumab plus Ipilimumab Combination Does Not Improve RFS over Nivolumab Alone in Patients with Stage IIIB-D or IV Melanoma
    Adjuvant Nivolumab plus Ipilimumab Combination Does Not Improve RFS over Nivolumab Alone in Patients with Stage IIIB-D or IV MelanomaOctober 4th, 2022
  • Join now to see all

Professional Memberships

Hospital Affiliations

Dr. Jason Luke, Dr. Jason Luke, MD, Dr. J Luke